Liposomal oligonucleotide compositions

US6096720A · kind A · utility

Assignee

• Novartis AG · CH

Inventors

• William Love · Horsham, GB
• Paul Leslie Nicklin · Ingelheim am Rhein, DE
• Karen Ophelia Hamilton · Lawrence, US
• Judith Ann Phillips · Sevenoaks, GB

Key dates

• Filing date: Apr 23, 1998
• Grant date: Aug 1, 2000
• Expiry date: Apr 23, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/1135
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A pharmaceutical composition comprising (A) an oligonucleotide 8 to 50 nucleotides in length, which is targeted to mRNA encoding human raf and is capable of inhibiting raf expression, entrapped in (B) sterically stabilized liposomes.